华海药业(600521) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the current period is CNY 1,892,528,117.08, a decrease of 10.70% compared to the same period last year[2] - The total profit for the current period is CNY 6,295,768.92, reflecting a significant decline of 98.23% year-on-year[2] - The net profit attributable to shareholders of the listed company is CNY -29,131,278.90, down 110.30% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is CNY -93,373,752.00, a decrease of 134.88% year-on-year[2] - Net profit for the first three quarters of 2025 was CNY 373,930,103.93, a decrease of 64.0% compared to CNY 1,037,247,794.71 in the same period of 2024[18] - Operating profit for the first three quarters of 2025 was CNY 555,157,968.34, down 57.8% from CNY 1,316,952,527.66 in the previous year[18] - Total comprehensive income for the first three quarters of 2025 was CNY 373,586,191.74, a decrease of 63.8% compared to CNY 1,031,127,531.22 in 2024[18] - Basic and diluted earnings per share for the first three quarters of 2025 were CNY 0.26, down from CNY 0.71 in the same period of 2024[18] Cash Flow - The net cash flow from operating activities for the current period is CNY 282,748,959.61, down 51.21% compared to the same period last year[2] - Cash flow from operating activities generated a net amount of CNY 652,386,672.14, down 65.3% from CNY 1,877,383,787.13 in the same period of 2024[21] - In the first three quarters of 2025, the net cash flow from operating activities was approximately $873.87 million, a decrease of 34% compared to $1.32 billion in the same period of 2024[32] - The company reported a total cash inflow from operating activities of approximately $4.86 billion in 2025, down from $5.27 billion in 2024[32] Assets and Liabilities - The total assets at the end of the reporting period amount to CNY 21,152,691,595.40, an increase of 4.40% from the end of the previous year[2] - Current assets as of September 30, 2025, totaled CNY 8,647,950,847.31, an increase from CNY 8,483,148,001.25 at the end of 2024[12] - Total assets reached CNY 21,152,691,595.40 as of September 30, 2025, compared to CNY 20,261,354,969.92 at the end of 2024[14] - Total liabilities increased to CNY 11,553,106,592.99 from CNY 11,241,320,819.01 in the previous year[14] - The total current liabilities rose to CNY 4.84 billion as of September 30, 2025, compared to CNY 4.49 billion at the end of 2024, reflecting an increase of about 7.8%[26] Shareholder Equity - The equity attributable to shareholders of the listed company is CNY 9,509,925,669.11, up 6.88% from the end of the previous year[2] - Shareholders' equity rose to CNY 9,599,585,002.41 as of September 30, 2025, compared to CNY 9,020,034,150.91 at the end of 2024[14] - The total owner's equity reached CNY 13.85 billion as of September 30, 2025, compared to CNY 12.55 billion at the end of 2024, representing an increase of about 10.4%[27] Research and Development - The company is actively promoting its third strategic transformation, focusing on "generic collaboration - global operations - value upgrade" strategy, which has led to a significant increase in R&D expenses by approximately 54% year-on-year[6] - Research and development expenses increased to CNY 829,481,556.27, up 20.7% from CNY 687,452,738.14 in the previous year[18] - Research and development expenses increased to CNY 350.26 million in the first three quarters of 2025, up from CNY 292.00 million in the same period of 2024, marking an increase of approximately 20%[28] Inventory and Operating Costs - The company reported a significant increase in inventory, which stood at CNY 3,813,635,900.31 as of September 30, 2025, compared to CNY 3,413,419,932.83 at the end of 2024[12] - Operating costs included CNY 2,454,250,665.30 for cost of goods sold, down from CNY 2,705,990,778.14 in the same period last year, indicating a reduction of 9.2%[16] - The company's inventory as of September 30, 2025, was CNY 2.44 billion, up from CNY 2.31 billion at the end of 2024, indicating an increase of about 5.7%[25] Investment and Financing Activities - Investment activities resulted in a net cash outflow of CNY 1,109,362,292.91, compared to a net outflow of CNY 1,185,287,884.07 in the same period of 2024[21] - Financing activities generated a net cash inflow of CNY 357,193,072.64, contrasting with a net outflow of CNY 606,211,733.26 in the previous year[23] - Cash inflow from financing activities totaled approximately $3.30 billion in 2025, up from $2.61 billion in 2024[33] Financial Ratios and Margins - The gross margin for the raw material drug business remains relatively stable at approximately 48.45% during the reporting period[7]